Price inquiry of ceritinib after medical insurance reimbursement 2025

Ceritinib is an oral second-generation ALK inhibitor specifically used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). ALK gene rearrangement is an important pathogenic driver in non-small cell lung cancer. Ceritinib inhibits the abnormally active ALK tyrosine kinase activity and blocks the proliferation and survival signals of tumor cells, thereby effectively controlling disease progression. As a targeted drug, ceritinib is particularly suitable for patients who are resistant or intolerant to the first-generation ALK inhibitor crizotinib.

Currently, ceritinib has been approved for marketing by the China National Medical Products Administration, markingALK targeted therapy has entered a new stage. In addition to being available for purchase in regular hospital pharmacies, ceritinib has also been included in the national medical insurance directory, significantly reducing the financial burden on patients. Its common specification is 150mg capsules, each box contains 150 capsules, which is convenient for patients to take it regularly for a long time. According to the latest medical insurance policy, the price of ceritinib has been significantly reduced after medical insurance reimbursement. The patient's out-of-pocket amount is approximately more than 10,000 yuan. The specific cost will fluctuate according to the medical insurance policies and reimbursement ratios of different provinces and cities. Overall, the inclusion in medical insurance makes this advanced targeted drug affordable for more patients.

The coverage of medical insurance not only improves the accessibility of ceritinib, but also encourages moreALK-positive patients to undergo early and accurate genetic testing to achieve precise treatment. It is worth noting that although ceritinib has significant efficacy, it still needs to be used under the guidance of professional doctors, and possible liver function abnormalities, gastrointestinal reactions and electrocardiogram changes should be properly monitored. In the future, with the accumulation of clinical experience and drug optimization, ceritinib is expected to further improve the survival and quality of life of patients with ALK-positive non-small cell lung cancer.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib